Fortress 10-Q: Q3 Revenue $19.2M, $7.9M Net Loss, $152.2M Cash and No Parent Debt
FBIO is trading near its 52-week low of $1.79 (9.2% above the low).
Summary
Fortress's Q3 10-Q confirms $19.2 million of revenue (up 9%) but a $(7.9) million loss attributable to common stockholders, alongside $152.2 million of cash and no parent-level debt after repaying Oaktree. The company remains locked out of Form S-3 while preferred dividends stay paused.
Key Events · Earnings and Guidance · FBIO
-
Q3 Revenue Grows 9% to $19.2M
Net revenue was $19.2 million versus $17.6 million a year earlier, with product revenue of $18.9 million driven by Emrosi at $9.0 million versus $4.9 million, partly offset by Qbrexza falling $1.8 million.
-
Quarter Swings to $7.9M Net Loss
Net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share, versus $3.7 million of income, or $0.13 per share, a year earlier; the prior period included a $17.7 million other-income gain that did not repeat.
-
Cash of $152.2M, Oaktree Repaid
Consolidated cash reached $152.2 million at September 30, 2026, of which $114.1 million sits at the parent and private subsidiaries; the Oaktree facility was paid off for $15.6 million on September 30, 2026, leaving Journey's $25.6 million SWK term loan as the only debt.
-
Preferred Dividend Pause Blocks Form S-3
Series A dividends remain paused, with $18.1 million of undeclared dividends accrued, so the company cannot use its $42.1 million 2024 shelf and would need a Form S-1 or private placement to raise equity.
Analysis · FBIO · Life Sciences
The headline numbers were already out in this morning's 8-K, but the 10-Q is where the quality of the quarter shows. Revenue of $19.2 million was up 9% on Emrosi's ramp to $9.0 million, yet the quarter flipped to a $(7.9) million loss attributable to common stockholders from $3.7 million of income a year earlier — the prior-year quarter carried a $17.7 million fair-value gain on the Crystalys stake that did not repeat, and Journey booked a $1.7 million charge above its accrual to settle a vendor dispute. The balance sheet is the real story: $152.2 million of consolidated cash, $114.1 million of it at the parent and private subsidiaries, and the Oaktree facility repaid in full on September 30, 2026, leaving only Journey's $25.6 million SWK term loan. Against that, the company still cannot use Form S-3 because Series A preferred dividends remain paused, with $18.1 million of undeclared dividends accrued — so any equity raise would be slower and costlier than a shelf takedown.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBIO was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.4M. The 52-week trading range was $1.79 to $4.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.